Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T ConsortiumLoretta J. Nastoupil, Frederick L. Locke, André Goy et al.|Journal of Clinical Oncology|2020Cited by 782
Management of Immunotherapy-Related Toxicities, Version 1.2019, NCCN Clinical Practice Guidelines in OncologyJohn A. Thompson, Jillian L. Scavone, Bryan J. Schneider et al.|Journal of the National Comprehensive Cancer Network|2019Cited by 560
NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020John A. Thompson, Anita M. Engh, Bryan J. Schneider et al.|Journal of the National Comprehensive Cancer Network|2020Cited by 484
Management of Immunotherapy-Related Toxicities, Version 1.2022, NCCN Clinical Practice Guidelines in OncologyJohn A. Thompson, Lisa Hang, Bryan J. Schneider et al.|Journal of the National Comprehensive Cancer Network|2022Cited by 416
Allogeneic BCMA-targeting CAR T cells in relapsed/refractory multiple myeloma: phase 1 UNIVERSAL trial interim resultsSham Mailankody, Shaji Kumar, Jeffrey Matous et al.|Nature Medicine|2023Cited by 239